93 related articles for article (PubMed ID: 21378474)
1. [Relationship between early lymphocyte recovery and prognosis after allogeneic hematopoietic stem cell transplantation for acute leukemia in remission].
Takasaki H; Numata A; Tachibana T; Tanaka M; Maruta A; Ishigatsubo Y; Kanamori H
Rinsho Ketsueki; 2011 Jan; 52(1):1-7. PubMed ID: 21378474
[TBL] [Abstract][Full Text] [Related]
2. [The correlation between early lymphocyte count post-allogeneic hematopoietic stem cell transplantation and prognosis in leukemia patients].
Wang JQ; Tan JW; Xu JH; Xiao Y; Meng FK; Zhang DH; Zhang YC
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):632-6. PubMed ID: 23134857
[TBL] [Abstract][Full Text] [Related]
3. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
4. Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.
Ferrá C; Sanz J; de la Cámara R; Sanz G; Bermúdez A; Valcárcel D; Rovira M; Serrano D; Caballero D; Espigado I; Morgades M; Heras I; Solano C; Duarte R; Barrenetxea C; García-Noblejas A; Díez-Martin JL; Iriondo A; Carreras E; Sierra J; Sanz MA; Ribera JM;
Biol Blood Marrow Transplant; 2010 Jul; 16(7):957-66. PubMed ID: 20144909
[TBL] [Abstract][Full Text] [Related]
5. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
6. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.
Fung HC; Stein A; Slovak Ml; O'donnell MR; Snyder DS; Cohen S; Smith D; Krishnan A; Spielberger R; Bhatia R; Bhatia S; Falk P; Molina A; Nademanee A; Parker P; Rodriguez R; Rosenthal J; Sweetman R; Kogut N; Sahebi F; Popplewell L; Vora N; Somlo G; Margolin K; Chow W; Smith E; Forman SJ
Biol Blood Marrow Transplant; 2003 Dec; 9(12):766-71. PubMed ID: 14677116
[TBL] [Abstract][Full Text] [Related]
7. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
8. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
9. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
10. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
[TBL] [Abstract][Full Text] [Related]
11. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
12. [Allogeneic peripheral blood stem cell transplantation for high-risk leukemia].
Huang X; Wang F; Guo N
Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1348-51. PubMed ID: 11930625
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Duarte RF; Canals C; Onida F; Gabriel IH; Arranz R; Arcese W; Ferrant A; Kobbe G; Narni F; Deliliers GL; Olavarría E; Schmitz N; Sureda A
J Clin Oncol; 2010 Oct; 28(29):4492-9. PubMed ID: 20697072
[TBL] [Abstract][Full Text] [Related]
14. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
Fuji S; Kim SW; Fukuda T; Mori S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Heike Y; Tobinai K; Tanosaki R; Takaue Y
Biol Blood Marrow Transplant; 2008 May; 14(5):510-7. PubMed ID: 18410893
[TBL] [Abstract][Full Text] [Related]
15. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
[TBL] [Abstract][Full Text] [Related]
16. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
17. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.
Kim SY; Lee DG; Kim MS; Kim HJ; Lee S; Min CK
Am J Hematol; 2008 Oct; 83(10):784-8. PubMed ID: 18661492
[TBL] [Abstract][Full Text] [Related]
18. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation.
Stussi G; Muntwyler J; Passweg JR; Seebach L; Schanz U; Gmür J; Gratwohl A; Seebach JD
Bone Marrow Transplant; 2002 Jul; 30(2):87-93. PubMed ID: 12132047
[TBL] [Abstract][Full Text] [Related]
19. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
20. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.
Maruyama D; Fukuda T; Kato R; Yamasaki S; Usui E; Morita-Hoshi Y; Kim SW; Mori S; Heike Y; Makimoto A; Tajima K; Tanosaki R; Tobinai K; Takaue Y
Biol Blood Marrow Transplant; 2007 Aug; 13(8):932-41. PubMed ID: 17640597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]